About GH Research

GH Research is a clinical-stage biopharmaceutical company developing mebufotenin-based therapies for treatment-resistant depression, bipolar II disorder, and postpartum depression. Their lead product, GH001, is a pulmonary inhalation formulation that aims to achieve rapid remission of depressive symptoms with a single dose, demonstrating a favorable tolerability profile and durable effects within a week.

```xml <problem> Treatment-resistant depression, bipolar II disorder, and postpartum depression are difficult to treat, often requiring multiple interventions and extended periods to achieve remission. Existing treatments may have slow onset of action, limited durability, and significant side effects, creating a substantial burden for patients and healthcare providers. </problem> <solution> GH Research is developing mebufotenin-based therapies, including GH001, a pulmonary inhalation formulation, designed for the rapid remission of depressive symptoms. GH001 aims to provide increased remission rates, faster onset of action, durable effects, and improved tolerability with a single-day administration. Early clinical data suggests that GH001 can induce remission of depressive symptoms within hours and maintain these effects for at least seven days, with a favorable tolerability profile. </solution> <features> - Pulmonary inhalation formulation (GH001) for rapid absorption and onset of action - Single-day dosing regimen to reduce treatment burden - Mebufotenin-based therapies (GH001, GH002, GH003) with different routes of administration (inhalation, intravenous, nasal) - Growing intellectual property portfolio covering novel uses, manufacturing methods, and aerosol compositions of mebufotenin - Individualized dosing regimen (IDR) to optimize treatment response </features> <target_audience> The primary target audience includes individuals suffering from treatment-resistant depression, bipolar II disorder with a depressive episode, and postpartum depression, as well as the healthcare providers who treat these conditions. </target_audience> ```

What does GH Research do?

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

GH Research

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

ghres.com LinkedIn Profile

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

Treatment-resistant depression, bipolar II disorder, and postpartum depression are difficult to treat, often requiring multiple interventions and extended periods to achieve remission. Existing treatments may have slow onset of action, limited durability, and significant side effects, creating a substantial burden for patients and healthcare providers.

Solution

GH Research is developing mebufotenin-based therapies, including GH001, a pulmonary inhalation formulation, designed for the rapid remission of depressive symptoms. GH001 aims to provide increased remission rates, faster onset of action, durable effects, and improved tolerability with a single-day administration. Early clinical data suggests that GH001 can induce remission of depressive symptoms within hours and maintain these effects for at least seven days, with a favorable tolerability profile.

Features

Pulmonary inhalation formulation (GH001) for rapid absorption and onset of action

Single-day dosing regimen to reduce treatment burden

Mebufotenin-based therapies (GH001, GH002, GH003) with different routes of administration (inhalation, intravenous, nasal)

Growing intellectual property portfolio covering novel uses, manufacturing methods, and aerosol compositions of mebufotenin

Individualized dosing regimen (IDR) to optimize treatment response

Target Audience

The primary target audience includes individuals suffering from treatment-resistant depression, bipolar II disorder with a depressive episode, and postpartum depression, as well as the healthcare providers who treat these conditions.